TY - JOUR
T1 - International Consensus Classification of Myeloid Neoplasms and Acute Leukemias
T2 - integrating morphologic, clinical, and genomic data
AU - Arber, Daniel A.
AU - Orazi, Attilio
AU - Hasserjian, Robert P.
AU - Borowitz, Michael J.
AU - Calvo, Katherine R.
AU - Kvasnicka, Hans Michael
AU - Wang, Sa A.
AU - Bagg, Adam
AU - Barbui, Tiziano
AU - Branford, Susan
AU - Bueso-Ramos, Carlos E.
AU - Cortes, Jorge E.
AU - Dal Cin, Paola
AU - DiNardo, Courtney D.
AU - Dombret, Hervé
AU - Duncavage, Eric J.
AU - Ebert, Benjamin L.
AU - Estey, Elihu H.
AU - Facchetti, Fabio
AU - Foucar, Kathryn
AU - Gangat, Naseema
AU - Gianelli, Umberto
AU - Godley, Lucy A.
AU - Gökbuget, Nicola
AU - Gotlib, Jason
AU - Hellström-Lindberg, Eva
AU - Hobbs, Gabriela S.
AU - Hoffman, Ronald
AU - Jabbour, Elias J.
AU - Kiladjian, Jean Jacques
AU - Larson, Richard A.
AU - Le Beau, Michelle M.
AU - Loh, Mignon L.C.
AU - Löwenberg, Bob
AU - Macintyre, Elizabeth
AU - Malcovati, Luca
AU - Mullighan, Charles G.
AU - Niemeyer, Charlotte
AU - Odenike, Olatoyosi M.
AU - Ogawa, Seishi
AU - Orfao, Alberto
AU - Papaemmanuil, Elli
AU - Passamonti, Francesco
AU - Porkka, Kimmo
AU - Pui, Ching Hon
AU - Radich, Jerald P.
AU - Reiter, Andreas
AU - Rozman, Maria
AU - Rudelius, Martina
AU - Savona, Michael R.
AU - Schiffer, Charles A.
AU - Schmitt-Graeff, Annette
AU - Shimamura, Akiko
AU - Sierra, Jorge
AU - Stock, Wendy A.
AU - Stone, Richard M.
AU - Tallman, Martin S.
AU - Thiele, Jürgen
AU - Tien, Hwei Fang
AU - Tzankov, Alexandar
AU - Vannucchi, Alessandro M.
AU - Vyas, Paresh
AU - Wei, Andrew H.
AU - Weinberg, Olga K.
AU - Wierzbowska, Agnieszka
AU - Cazzola, Mario
AU - Döhner, Hartmut
AU - Tefferi, Ayalew
N1 - Publisher Copyright:
© 2022 American Society of Hematology
PY - 2022/9/15
Y1 - 2022/9/15
N2 - The classification of myeloid neoplasms and acute leukemias was last updated in 2016 within a collaboration between the World Health Organization (WHO), the Society for Hematopathology, and the European Association for Haematopathology. This collaboration was primarily based on input from a clinical advisory committees (CACs) composed of pathologists, hematologists, oncologists, geneticists, and bioinformaticians from around the world. The recent advances in our understanding of the biology of hematologic malignancies, the experience with the use of the 2016 WHO classification in clinical practice, and the results of clinical trials have indicated the need for further revising and updating the classification. As a continuation of this CAC-based process, the authors, a group with expertise in the clinical, pathologic, and genetic aspects of these disorders, developed the International Consensus Classification (ICC) of myeloid neoplasms and acute leukemias. Using a multiparameter approach, the main objective of the consensus process was the definition of real disease entities, including the introduction of new entities and refined criteria for existing diagnostic categories, based on accumulated data. The ICC is aimed at facilitating diagnosis and prognostication of these neoplasms, improving treatment of affected patients, and allowing the design of innovative clinical trials.
AB - The classification of myeloid neoplasms and acute leukemias was last updated in 2016 within a collaboration between the World Health Organization (WHO), the Society for Hematopathology, and the European Association for Haematopathology. This collaboration was primarily based on input from a clinical advisory committees (CACs) composed of pathologists, hematologists, oncologists, geneticists, and bioinformaticians from around the world. The recent advances in our understanding of the biology of hematologic malignancies, the experience with the use of the 2016 WHO classification in clinical practice, and the results of clinical trials have indicated the need for further revising and updating the classification. As a continuation of this CAC-based process, the authors, a group with expertise in the clinical, pathologic, and genetic aspects of these disorders, developed the International Consensus Classification (ICC) of myeloid neoplasms and acute leukemias. Using a multiparameter approach, the main objective of the consensus process was the definition of real disease entities, including the introduction of new entities and refined criteria for existing diagnostic categories, based on accumulated data. The ICC is aimed at facilitating diagnosis and prognostication of these neoplasms, improving treatment of affected patients, and allowing the design of innovative clinical trials.
UR - http://www.scopus.com/inward/record.url?scp=85135873864&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85135873864&partnerID=8YFLogxK
U2 - 10.1182/blood.2022015850
DO - 10.1182/blood.2022015850
M3 - Article
C2 - 35767897
AN - SCOPUS:85135873864
SN - 0006-4971
VL - 140
SP - 1200
EP - 1228
JO - Blood
JF - Blood
IS - 11
ER -